Evaluation of the vascular targeting agent combretastatin A-4 prodrug on retinal neovascularization in the galactose-fed dog

Journal of Ocular Pharmacology and Therapeutics

Volumn 23, Issue 2, 2007, Pages 132-142

  Kador, Peter F ^a,b,c   Blessing, Karen ^a,b   Randazzo, James ^b   Makita, Jun ^b,d   Wyman, Milton ^a  

^a NATIONAL EYE INSTITUTE   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^d UNIVERSITY OF FUKUI   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

COMBRETASTATIN A4; FLUORESCEIN; GALACTOSE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; APHAKIA; ARTICLE; CONTROLLED STUDY; CORNEA EDEMA; CORNEA LIMBUS; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; EVALUATION; FLUORESCENCE ANGIOGRAPHY; NONHUMAN; PILOT STUDY; RETINA NEOVASCULARIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APHAKIA; DIABETIC RETINOPATHY; DISEASE MODELS, ANIMAL; DOGS; FLUORESCEIN ANGIOGRAPHY; GALACTOSE; INJECTIONS; INTRAOCULAR PRESSURE; PRODRUGS; RETINAL NEOVASCULARIZATION; RETINAL VESSELS; STILBENES;

EID: 34247383040     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.2006.0103     Document Type: Article

References (42)

1. Gariano, R.F., and Gardner, T.W. Retinal angiogenesis in development and disease. Nature 438:960-966, 2005.
2. American Academy of Ophthalmology. Diabetic Retinopathy Preferred Practice Pattern. Online document at: http://www.aao.org/education/library/ppp/ upload/Diabetic-Retinopathy.pdf Accessed July 30, 2006.
3. Mousa, S.A., and Mousa, A.S. Angiogenesis inhibitors: Current and future directions. Curr. Pharm. Des. 10:1-9, 2004.
4. Neri, D., and Bicknell, R. Tumour vascular targeting. Nat. Rev. Cancer 5:436-446, 2005.
5. Tozer, G.M., Kanthou, C., and Baguley, B.C. Disrupting tumour blood vessels. Nat. Rev. Cancer 5:423-435, 2005.
6. Ferrara, N. Vascular endothelial growth factor: Basic science and clinical progress. Endocr. Rev. 25:581-611, 2004.
7. Attard, G., Greystoke, A., Kaye, S., et al. Update on tubulin-binding agents. Pathol. Biol. (Paris) 54:72-84, 2006.
8. Young, S.L., and Chaplin, D.J. Combretastatin A4 phosphate: Background and current clinical status. Exp. Opin. Invest. Drugs 13:1171-1182, 2004.
9. Woods, J.A., Hadfield, J.A., Pettit, G.R., et al. The interaction with tubulin of a series of stilbenes based on combretastatin A-4. Br. J. Cancer 71:705-711, 1995.
10. Pettit, G.R., Temple, C., Jr., Narayanan, V.L., et al. Antineoplastic agents 322: Synthesis of combretastatin A-4 prodrugs. Anticancer Drug Des. 10:299-309, 1995.
11. Horsman, M.R., Ehrnrooth, E., Ladekarl, M., et al. The effect of combretastatin A-4 disodium phosphate in a C3H mouse mammary carcinoma and a variety of murine spontaneous tumors. Int. J. Radiat. Oncol. Biol. Phys. 42:895-898, 1998.
12. Dark, G.G., Hill, S.A., Prise, V.E., et al. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res. 57:1829-1834, 1997.
13. Iyer, S., Chaplin, D.J., Rosenthal, D.S., et al. Induction of apoptosis in proliferating human endothelial cells by the tumor-specific antiangiogenesis agent combretastatin A-4. Cancer Res. 58:4510-4514, 1998.
14. Nabha, S.M., Mohammad, R.M., Dandashi, M.H., et al. Combretastatin A-4 prodrug induces mitotic catastrophe in chronic lymphocytic leukemia cell line independent of caspase activation and poly(ADP-ribose) polymerase cleavage. Clin. Cancer Res. 8:2735-2741, 2002.
15. Galbraith, S.M., Chaplin, D.J., Lee, F., et al. Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo. Anticancer Res. 21:93-102, 2001.
16. Kanthou, C., and Tozer, G.M. The tumor vascular targeting agent combretastatin A-4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells. Blood 99:2060-2069, 2002.
17. Grosios, K., Holwell, S.E., McGown, A.T., et al. In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug. Br. J. Cancer 81:1318-1327, 1999.
18. Tozer, G.M., Prise, V.E., Wilson, J., et al. Combretastatin A-4 phosphate as a tumor vascular-targeting agent: Early effects in tumors and normal tissues. Cancer Res. 59:1626-1634, 1999.
19. Dowlati, A., Robertson, K., Cooney, M., et al. A phase I pharmacokinetic and translarional study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res. 62:3408-3416, 2002.
20. Cooney, M.M., Radivoyevitch, T., Dowlati, A., et al. Cardiovascular safety profile of combretastatin a-4 phosphate in a single-dose phase I study in patients with advanced cancer. Clin. Cancer Res. 10:96-100, 2004.
21. Stevenson, J.P., Rosen, M., Sun, W., et al. Phase I trial of the antivascular agent combretastatin A-4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. J. Clin. Oncol. 21:4428-4438, 2003.
22. Dziba, J.M., Marcinek, R., Venkataraman, G., et al. Combretastatin A-4 phosphate has primary antineoplastic activity against human anaplastic thyroid carcinoma cell lines and xenograft tumors. Thyroid 12:1063-1070, 2002.
23. Griggs, J., Hesketh, R., Smith, G.A., et al. Combretastatin A-4 disrupts neovascular development in non-neoplastic tissue. Br. J. Cancer 84:832-835, 2001.
24. Escalona-Benz, E., Jockovich, M.E., Murray, T.G., et al. Combretastatin A-4 prodrug in the treatment of a murine model of retinoblastoma. Invest. Ophthalmol. Vis. Sci. 46:8-11, 2005.
25. Griggs, J., Skepper, J.N., Smith, G.A., et al. Inhibition of proliferative retinopathy by the antivascular agent combretastatin A-4. Am. J. Pathol. 160:1097-1103, 2002.
26. Nambu, H., Nambu, R., Melia, M., et al. Combretastatin A-4 phosphate suppresses development and induces regression of choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. 44:3650-3655, 2003.
27. Campochiaro, P.A., and Hackett, S.F. Ocular neovascularization: A valuable model system. Oncogene 22:6537-6548, 2003.
28. Michels, S., Schmidt-Erfurth, U., and Rosenfeld, P.J. Promising new treatments for neovascular age-related macular degeneration. Exp. Opin. Invest. Drugs 15:779-793, 2006.
29. Kador, P.F., Takahashi, Y., Akagi, Y., et al. Effect of galactose diet removal on the progression of retinal vessel changes in galactose-fed dogs. Invest. Ophthalmol. Vis. Sci. 43:1916-1921, 2002.
30. Kador, P.F., Takahashi, Y., Wyman, M., et al. Diabeteslike proliferative retinal changes in galactose-fed dogs. Arch. Ophthalmol. 113:352-354, 1995.
31. Takahashi, Y., Wyman, M., Ferris, F., III, et al. Diabeteslike preproliferative retinal changes in galactose-fed dogs. Arch. Ophthalmol. 110:1295-1302, 1992.
32. Cusick, M., Chew, E.Y., Ferris, F., III, et al. Effects of aldose reductase inhibitors and galactose withdrawal on fluorescein angiographic lesions in galactose-fed dogs. Arch. Ophthalmol. 121:1745-1751, 2003.
33. Kobayashi, T., Kubo, E., Takahashi, Y., et al. Retinal vessel changes in galactose-fed dogs. Arch. Ophthalmol. 116:785-789, 1998.
34. Lund-Andersen, H. Mechanisms for monitoring changes in retinal status following therapeutic intervention in diabetic retinopathy. Surv. Ophthalmol. 47(Suppl. 2):S270-S271, 2002.
35. Taraboletti, G., and Giavazzi, R. Modelling approaches for angiogenesis. Eur. J. Cancer 40:881-889, 2004.
36. Madan, A., and Penn, J.S. Animal models of oxygen-induced retinopathy. Front. Biosci. 8:d1030-d1043, 2003.
37. Chang, J.H., Gabison, E.E., Kato, T., et al. Corneal neovascularization. Curr. Opin. Ophthalmol. 12:242-249, 2001.
38. Das, A., and McGuire, P.G. Retinal and choroidal angiogenesis: Pathophysiology and strategies for inhibition. Prog. Retin. Eye Res. 22:721-748, 2003.
39. West, C.M., and Price, P. Combretastatin A-4 phosphate. Anticancer Drugs 15:179-187, 2004.
40. Avery, R.L., Pearlman, J., Pieramici, D.J., et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 113:1695 e1-15, 2006.
41. Danis, R.P., Bingaman, D.P., Jirousek, M., et al. Inhibition of intraocular neovascularization caused by retinal ischemia in pigs by PKCbeta inhibition with LY333531. Invest. Ophthalmol. Vis. Sci. 39:171-179, 1998.
42. The PKC-DRS Study Group. The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: Initial results of the Protein Kinase C Beta Inhibitor Diabetic Retinopathy Study (PKC-DRS) multicenter, randomized, clinical trial. Diabetes 54:2188-2197, 2005.